Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos A Garay

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Cureus|September 23, 2025
Stump Appendicitis After Appendectomy: A Case ReportLuis F Ochoa, Carlos A Garay, Alexis J Lira, et al.
Journal of Medical Economics|July 20, 2012
Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinomaMichael K Wong, Ateesha F Mohamed, A Brett Hauber, et al.
Cureus|March 26, 2026
Diagnostic and Therapeutic Approach to External Frontal Lesions: A Report of Two CasesLuis F Ochoa, Vanessa Galvan, Carlos A Garay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancerNancy Kemeny, Carlos A Garay, Jayne Gurtler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Cureus|September 23, 2025
Stump Appendicitis After Appendectomy: A Case ReportLuis F Ochoa, Carlos A Garay, Alexis J Lira, et al.
Journal of Medical Economics|July 20, 2012
Patients rank toxicity against progression free survival in second-line treatment of advanced renal cell carcinomaMichael K Wong, Ateesha F Mohamed, A Brett Hauber, et al.
Cureus|March 26, 2026
Diagnostic and Therapeutic Approach to External Frontal Lesions: A Report of Two CasesLuis F Ochoa, Vanessa Galvan, Carlos A Garay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2004
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancerNancy Kemeny, Carlos A Garay, Jayne Gurtler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trialMace L Rothenberg, Amit M Oza, Robert H Bigelow, et al.
Pageof 1